Key result
SGLT2 inhibitors are newly initiated in ~17% of untreated patients within 30 days post-TAVI.
Why the study?
Overall SGLT2 inhibitor use after TAVI combines continuation and new initiation, necessitating characterization of these distinct prescribing processes and the clinical profiles accompanying initiation.
Cohort (n=653)
No
After TAVI, high rates of SGLT2 inhibitor continuation (95.8%) coexisted with limited new initiation (17.0%), highlighting the need to distinguish between continuation and new prescribing when evaluating post-TAVI medical therapy.
Answers are grounded in this paper and cite their sources.
Low new SGLT2 inhibitor initiation post-TAVI should not yet change practice; leaves open optimal strategies and outcome effects in prospective data.
BACKGROUND: Overall sodium-glucose cotransporter 2 (SGLT2) inhibitor use after transcatheter aortic valve implantation (TAVI) combines continuation and new initiation. We characterized these distinct prescribing processes and the clinical profiles accompanying initiation. AIMS AND METHODS: This retrospective single-center registry included 653 patients undergoing TAVI in 2022-2025. Exposure was assessed within 90 days before and 30 days after TAVI using discharge summaries and electronic medical records. The primary measure was initiation among previously untreated patients. Admission and wait-list N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurements were summarized separately. RESULTS: Early medication status was known in 639 patients; 260 (40.7%) received SGLT2 inhibitors. Among 638 patients with paired records, 184 continued therapy, 76 initiated, eight did not continue, and 370 had no use in either window. Continuation occurred in 184/192 previously treated patients (95.8%), whereas initiation occurred in 76/446 previously untreated patients (17.0%; 95% confidence interval, 13.8-20.8). Initiation was 70/351 (19.9%) in a secondary subgroup with selected clinical risk features, without established trial eligibility. Admission NT-proBNP was available in 590 patients (90.4%); wait-list values were available in 356, including 349 with both assessments. Initiators had lower ejection fraction and higher admission NT-proBNP. Urinary tract infection explained four of eight non-continuations. CONCLUSIONS: High continuation coexisted with limited new initiation. Transition-specific reporting clarifies early prescribing and supports individualized reassessment after TAVI, but does not establish treatment effects or the appropriateness of individual non-prescription decisions.
No takes yet. Share an insight, caveat, or question.
Jurin et al. (2026) conducted a cohort in Transcatheter aortic valve implantation (TAVI) (n=653). Sodium-glucose cotransporter 2 (SGLT2) inhibitor was evaluated on SGLT2 inhibitor initiation among previously untreated patients within 30 days after TAVI (95% CI 13.8-20.8). SGLT2 inhibitor therapy was newly initiated within 30 days post-TAVI in 17.0% of previously untreated patients, compared with 95.8% continuation among prior users.
Synapse has enriched 10 related papers. Consider them for comparative context: